期刊
VIRUSES-BASEL
卷 6, 期 12, 页码 4811-4838出版社
MDPI
DOI: 10.3390/v6124811
关键词
retrovirology; alpharetroviral vector; gene therapy; clinical translation; regulatory requirements; vector safety
类别
资金
- Deutsche Forschungsgemeinschaft [SFB738, EXC 62/1, SPP1230]
- Bundesministerium fur Bildung und Forschung (BMBF, Joint Research Project IFB-Tx, PidNet)
- DAAD (Modern Applications in Biotechnology)
- European Union (FP7 project PERSIST)
Gene therapy using integrating retroviral vectors has proven its effectiveness in several clinical trials for the treatment of inherited diseases and cancer. However, vector-mediated adverse events related to insertional mutagenesis were also observed, emphasizing the need for safer therapeutic vectors. Paradoxically, alpharetroviruses, originally discovered as cancer-causing agents, have a more random and potentially safer integration pattern compared to gammaretro- and lentiviruses. In this review, we provide a short overview of the history of alpharetroviruses and explain how they can be converted into state-of-the-art gene delivery tools with improved safety features. We discuss development of alpharetroviral vectors in compliance with regulatory requirements for clinical translation, and provide an outlook on possible future gene therapy applications. Taken together, this review is a broad overview of alpharetroviral vectors spanning the bridge from their parental virus discovery to their potential applicability in clinical settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据